Treatment options for
metastatic urothelial carcinoma:

Challenge the expert

Publication date: 13 February 2023

Axel Merseburger
Enrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s viewpoint to create a lively debate.

Watch these two video discussions to expand your knowledge of first- and subsequent-line immunotherapy treatment options and see how the experts work together to find possible solutions.

After watching both videos, please remember to complete the evaluation survey as your feedback helps us to deliver the best learning experience.

Part 1: Therapy options in first-line and maintenance settings for patients with mUC

Part 2: Subsequent-line immunotherapy options for patients with mUC

About this activity

Learning objectives

After studying the content, participants will be able to:

  • discuss current and emerging immune-based regimens for mUC and the clinical data supporting them
  • debate how to best integrate and sequence new immunotherapy options in the landscape of mUC to achieve optimal clinical outcomes
  • evaluate the importance of predictive factors to enhance patient selection and move to personalized care

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.